Kalantari Hamid, Sabbaghian Marjan, Vogiatzi Paraskevi, Rambhatla Amarnath, Agarwal Ashok, Colpi Giovanni M, Sadighi Gilani Mohammad Ali
Department of Andrology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.
Andromed Health & Reproduction, Reproductive Health Diagnostic Center, Athens, Greece.
World J Mens Health. 2023 Jul;41(3):659-670. doi: 10.5534/wjmh.220089. Epub 2023 Jan 1.
Despite all past efforts, the current guidelines are not explicit enough regarding the indications for performing azoospermia factor (AZF) screening and karyotype, burdening clinicians with the decision to assess whether such tests are meaningful for the infertile male patient. These assessments can be costly and it is up to the healthcare practitioner to decide which are necessary and to weigh the benefits against economic/psychological harm. The aim of this study is to address such gaps and provide update on current management options for this group of patients.
To address such gaps in male infertility management and to elucidate whether AZF screening is indicated in individuals who concomitantly harbor chromosomal abnormalities we conducted a retrospective cohort analysis of 10,388 consecutive patients with non-obstructive azoospermia (NOA) and severe oligozoospermia.
Previously, it has been suggested that all NOA cases with chromosomal defects, except males with 46,XY/45,X karyotype, have no indication for AZF screening. Our findings revealed that cases carrying the following chromosomal abnormalities inv(Y)(p11.2q12); idic(Y)(q11.2); 46,XY,r(Y); idic(Y)(p11.2) and der(Y;Autosome) (76/169; 44.9%; 95% CI, 37.7-52.5) should also be referred for AZF deletion screening. Here, we also report the correlation between sperm count and AZF deletions as a secondary outcome. In accordance with previously reported data from North America and Europe, our data revealed that only 1% of cases with >1×10 sperm/mL had Y chromosome microdeletions (YCMs).
In the era of assisted reproduction, finding cost-minimization strategies in infertility clinics without affecting the quality of diagnosis is becoming one of the top prioritized topics for future research. From a diagnostic viewpoint, the results reflect a need to reconsider the different karyotype presentations and the sperm count thresholds in male infertility guidelines as indicators for YCM screening during an infertility evaluation.
尽管过去已做出诸多努力,但当前指南在无精子症因子(AZF)筛查和核型分析的适应证方面仍不够明确,这使得临床医生需自行决定此类检查对男性不育患者是否有意义。这些评估可能成本高昂,而医疗从业者需决定哪些评估是必要的,并权衡其益处与经济/心理伤害。本研究旨在填补此类空白,并提供针对这组患者当前管理方案的最新信息。
为填补男性不育管理方面的此类空白,并阐明在伴有染色体异常的个体中是否需要进行AZF筛查,我们对10388例连续的非梗阻性无精子症(NOA)和严重少精子症患者进行了回顾性队列分析。
此前有人提出,除46,XY/45,X核型的男性外,所有染色体缺陷的NOA病例均无需进行AZF筛查。我们的研究结果显示,携带以下染色体异常inv(Y)(p11.2q12);idic(Y)(q11.2);46,XY,r(Y);idic(Y)(p11.2)和der(Y;常染色体)(76/169;44.9%;95%可信区间,37.7 - 52.5)的病例也应进行AZF缺失筛查。在此,我们还报告了精子计数与AZF缺失之间的相关性作为次要结果。与北美和欧洲先前报道的数据一致,我们的数据显示,精子浓度>1×10精子/mL的病例中只有1%存在Y染色体微缺失(YCMs)。
在辅助生殖时代,在不影响诊断质量的情况下,在不育诊所寻找成本最小化策略正成为未来研究的首要优先课题之一。从诊断角度来看,这些结果反映出有必要重新考虑男性不育指南中不同的核型表现和精子计数阈值,将其作为不育评估期间YCM筛查的指标。